FDA supplemental approval: Hydromorphone Hydrochloride (REMS)

AI Summary

This is a regulatory action: the FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) application for hydromorphone hydrochloride tablets (2 mg, 4 mg, and 8 mg oral formulations) manufactured by Genus, effective 18 June 2026. The record does not contain clinical trial results, efficacy data, or safety outcomes; it documents only the regulatory decision to require or modify risk mitigation measures for this opioid product.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for hydromorphone hydrochloride tablets; this is a regulatory action, not a clinical efficacy study.

Reported figures

Quoted from the source exactly as published.

Caveats

• This is a regulatory action record, not a clinical study; no trial outcomes, efficacy data, safety results, or comparative effectiveness information is reported.
• The specific content of the REMS requirements is not detailed in this record.
• No information on the rationale for the supplement or any new safety signals is provided.
• The record does not report clinical trial results, adverse events, or efficacy endpoints.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.